You are here: Industry Insights > Cepheid

News List

Cepheid Receives CE-IVD Registration for SARS-CoV-2, Flu A, Flu B, RSV Combination Test americanpharmaceuticalreview
December 10, 2020
Cepheid announced the CE-IVD marking of Xpert® Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample.
Cepheid Receives EUA for SARS-CoV-2, Flu A, Flu B and RSV Combination Test americanpharmaceuticalreview
October 09, 2020
Cepheid has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19 ...
Cepheid Announces Development of Combination Test for SARS-CoV-2, Flu A, Flu B, RSV americanpharmaceuticalreview
June 18, 2020
Cepheid announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19 during the upcoming respiratory virus season.
Cepheid Receives Emergency Use Authorization for Rapid SARS-CoV-2 Test americanpharmaceuticalreview
March 25, 2020
Cepheid has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2.